Who are Ivacaftor and Symdeko's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ivacaftor-and-symdeko.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Ivacaftor and Symdeko — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ivacaftor and Symdeko (Ivacaftor and Symdeko) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CFTR modulator (potentiator and corrector combination). Area: Pulmonary/Respiratory.

marketed CFTR modulator (potentiator and corrector combination) CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Pulmonary/Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Ivacaftor and Symdeko (Ivacaftor and Symdeko) — University of Alabama at Birmingham. Ivacaftor is a CFTR potentiator that increases the opening probability of the cystic fibrosis transmembrane conductance regulator (CFTR) channel, while Symdeko combines ivacaftor with lumacaftor, a CFTR corrector that helps misfolded CFTR protein reach the cell surface.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ivacaftor and Symdeko TARGET	Ivacaftor and Symdeko	University of Alabama at Birmingham	marketed	CFTR modulator (potentiator and corrector combination)	CFTR (Cystic Fibrosis Transmembrane Conductance Regulator)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CFTR modulator (potentiator and corrector combination) class)

University of Alabama at Birmingham · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ivacaftor and Symdeko — Competitive Intelligence Brief. https://druglandscape.com/ci/ivacaftor-and-symdeko. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab